GENPREX INC (GNPX)
US3724462037 - Common Stock
GENPREX INC
NASDAQ:GNPX (4/29/2024, 7:03:22 PM)
After market: 2.17 -0.12 (-5.24%)2.29
+0.08 (+3.62%)
Company Profile
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 28 full-time employees. The company went IPO on 2018-03-29. The firm is focused on the development of gene-based therapies for patients with unmet medical needs. The firm's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The firm is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
Company Info
GENPREX INC
1601 Trinity Street, Bldg. B, Suite 3.322
Austin TEXAS 78712
P: 15125377997
CEO: J. Rodney Varner
Employees: 28
Website: https://www.genprex.com/
GNPX News
21 days ago - Genprex, Inc.Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
a month ago - Genprex, Inc.Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
a month ago - Genprex, Inc.Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
a month ago - Genprex, Inc.Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
3 months ago - Genprex, Inc.Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
3 months ago - Genprex, Inc.Genprex to Present at Upcoming BIO CEO & Investor Conference/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
GNPX Twits
Here you can normally see the latest stock twits on GNPX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
